A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

To join this study, you would need to have pancreatic cancer that has spread, and tests must show that your cancer has a specific genetic change called a KRAS G12D mutation. This study is for people who have not yet received any treatment for their advanced cancer.

You also need to be generally well enough to take part in a study like this. Doctors will check your overall health and how active you are. Your body's organs, like your liver and kidneys, need to be working properly, which will be checked with blood tests.

There are also reasons why someone might not be able to join. For example, if you've already had treatment with a similar type of drug called a KRAS inhibitor, or if you have an active infection. People with cancer that has spread to the brain and is causing problems would also not be able to participate. Your medical team will go through all the detailed requirements with you to see if this study could be a good fit.

If you decide to take part in this study, you would be given either the new medicine (INCB161734) with chemotherapy, or a dummy treatment (placebo) with chemotherapy. You wouldn't know which group you are in, and neither would your doctors, to ensure the results are accurate. You would have regular appointments with the study team for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working against the cancer. You would also need to take the study medication as directed.

The study would involve regular visits to the hospital or clinic for these check-ups and treatments. The exact number of visits and the full duration of your participation would depend on how your treatment is going and how long the study continues to follow participants. The study team will explain the full schedule to you in detail.